BACKGROUND Atomoxetine is FDA-approved as a treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years to adult. Among pediatric clinical trials of atomoxetine to date, six with a randomized, double-blind, placebo-controlled design were used in this meta-analysis. The purpose of this article is to describe and compare the treatment response and tolerability of atomoxe...

Introduction: The prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in the world is estimated at about 5%. Among adults, it occurs with a frequency 2.5%. This syndrome can significantly impair functioning various areas life. There treatment to reduce symptoms. Aim study: aim study was collect and analyze publications on attention deficit hyperactivity disorder - symptoms, diagnosis ...

OBJECTIVE Numerous investigations have examined the efficacy of pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in children. However, relatively few studies have addressed the impact of treatment on long-term subjective, psychosocial outcomes, such as health-related quality of life (HRQL). This study examines the long-term effects of pharmacological treatment with ...

1Medication Management Coordinator, Fraser Health Authority, Vancouver, British Columbia 2Clinical Consultant in Child and Adolescent Psychiatry and Assistant Professor (Part-Time), UBC Faculty of Pharmaceutical Sciences, Vancouver, British Columbia introduction Over the last decade, several advances have been made in the pharmacological treatment of ADHD. Novel medications, longer acting prepa...

OBJECTIVE Recent case reports suggest a link between reduced melanocortinergic tone and both obesity and attention deficit / hyperactivity disorder (ADHD). We present the case of a 13-year-old, male, obese MC4R mutation carrier with ADHD. CASE REPORT The boy carries a heterozygous mutation in the melanocortin 4 receptor gene (MC4R; Met281Val), that leads to a reduced receptor function. Domina...

Sudden unexpected death in epilepsy (SUDEP) is the leading cause of mortality patients with intractable epilepsy. However, pathogenesis SUDEP seems to be poorly understood. Our previous findings showed that incidence seizure-induced respiratory arrest (S-IRA) was markedly reduced by atomoxetine a murine model. Because central norepinephrine ?-1 receptor (NE?-1R) plays vital role regulating func...

Abstract Attention-deficit hyperactivity disorder (ADHD) with its high prevalence is a growing area of concern and research, whereas exact underlying pathophysiology remains unknown. Behavioral therapy multiple medications include methylphenidate, atomoxetine, amphetamines while trigeminal nerve stimulator (TNS) the first medical device in ADHD FDA approval. The aim this article to evaluate lat...